Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: A 3D printing device (100), comprising a melt extrusion module (102), a printing module (103), and a platform module (104). The melt extrusion module (102) comprises a processing chamber (121) consisting of a feed inlet (124) and a discharge outlet (125), as well as an extrusion means (122) and a heating means (123) disposed at the processing chamber; the melt extrusion module (102) is configured to receive an initial material from the feed inlet (124) of the processing chamber (121), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet (125) of the processing chamber (121). The printing module (103) is communicated with the discharge outlet (125) of the processing chamber (121) and is provided with a nozzle (131); the printing module (103) is configured to receive the molten body extruded from the discharge outlet (125) of the processing chamber (121) and guide the molten body to be extruded out of the nozzle (131).

Abstract: A light-transmitting display panel, display panel and display apparatus. The light-transmitting display panel includes a first pixel array including a first minimum repeating unit. The first minimum repeating unit includes at least one light-transmitting column unit. The at least one light-transmitting column unit has a central axis parallel to an extending direction of the at least one light-transmitting column unit. The at least one light-transmitting column unit includes a plurality of first sub-pixels spaced apart from one another in the extending direction of the at least one light-transmitting column unit. At least one of the first sub-pixels in the at least one light-transmitting column unit is set to deviate from the central axis.

Abstract: The present disclosure generally relates to an additive manufacturing system. The system can comprise a material supply module for melting and pressurizing a printing material; a micro-screw printing head comprising: a micro-screw comprising a threaded stem portion and a conical head portion, wherein the threaded stem portion is threaded throughout its length for volume measurement; a sleeve, and a nozzle, wherein a distal end of the nozzle comprises: a conical inner surface, and an outlet port for dispensing the print material, wherein the conical inner surface of the nozzle is configured to be in contact with the conical head portion of the micro-screw to stop dispensing the printing material at the nozzle when the micro-screw printing head is in a closed position; a driving module comprising: a rotation motor for driving a rotating motion of the micro-screw, and an actuator for driving a vertical motion of the micro-screw.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: The present invention relates to the field of catalysts, and provides a porous layered transition metal dichalcogenide (TMD) and a preparation method and use thereof. The preparation method includes the following steps: (1) mixing silica microspheres, a transition metal salt and an elemental chalcogen, and pressing to obtain a tablet, the silica microspheres having a same or different particle diameters; and (2) sintering the tablet under hydrogen, and removing the silica microspheres to obtain the porous layered TMD. The porous layered TMD prepared by the method of the present invention has a high lattice edge exposure, which provides more active sites and higher catalytic activity, so the porous layered TMD can effectively catalyze the oxidation of alcohols to aldehydes or sulfides to sulfoxides under visible light irradiation.

Abstract: A system includes: a pre-charge circuit configured to produce direct current (DC) electrical power; a common DC bus; and a plurality of inverters, each inverter including: a local DC bus; a capacitor network connected to the local DC bus; an electrical network connected to the local DC bus, the electrical network configured to generate an alternating current (AC) drive signal; and a plurality of switching assemblies, each switching assembly being associated with one of the inverters, and each switching assembly configured to control whether the local DC bus and the capacitor network of the associated inverter are electrically connected to the common DC bus or to the pre-charge circuit.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: The present disclosure, in some aspects, is directed to methods of designing an oral drug dosage form formulated and configured to have a desired pharmacokinetic profile. In other aspects, the present disclosure is directed to oral drug dosage forms having a desired pharmacokinetic profile, and methods of making, such as three-dimensional printing, such oral drug dosage forms.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: A 3D printing device (100), comprising a melt extrusion module (102), a printing module (103), and a platform module (104). The melt extrusion module (102) comprises a processing chamber (121) consisting of a feed inlet (124) and a discharge outlet (125), as well as an extrusion means (122) and a heating means (123) disposed at the processing chamber; the melt extrusion module (102) is configured to receive an initial material from the feed inlet (124) of the processing chamber (121), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet (125) of the processing chamber (121). The printing module (103) is communicated with the discharge outlet (125) of the processing chamber (121) and is provided with a nozzle (131); the printing module (103) is configured to receive the molten body extruded from the discharge outlet (125) of the processing chamber (121) and guide the molten body to be extruded out of the nozzle (131).

Abstract: A dosage form of controlled release at specific gastrointestinal sites is provided. The dosage form includes a shell defining a first and a second compartment, a first active pharmaceutical ingredient (API) loaded in the first compartment, and a second API loaded in the second compartment, wherein the first API and the second API can be the same or different. The shell includes a first material soluble in a first gastrointestinal site and a second material soluble in a second gastrointestinal site.

Abstract: Disclosed are Lactobacillus rhamnosus strain 753 and uses thereof, a silage additive and silage. Lactobacillus rhamnosus strain 753 is deposited in China General Microbiological Culture Collection Center with an accession number of CGMCC 18233. Lactobacillus rhamnosus strain 753 can improve the quality of silage in a high-temperature and high-humidity region, and the silage processed by Lactobacillus rhamnosus strain 753 has good stability and low pH, low aflatoxin B1 content and less dry matter loss. In addition, secondary fermentation can be avoided in the silage processed by Lactobacillus rhamnosus strain 753 when a silo or bale for silage is opened.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: The present disclosure provides oral drug dosage forms comprising: (a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and (b) an erodible stimulant material admixed with an ADHD stimulant, wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a desired non-stimulant release profile and the ADHD stimulant is released according to a desired stimulant release profile. In some embodiment, the ADHD non-stimulant is released according to a sustained release profile. In some embodiments, the ADHD stimulant is released according to an immediate release profile. The oral drug dosage forms of the present disclosure are useful for the treatment of attention deficit hyperactivity disorder (ADHD). Also provided herein are methods of designing and manufacturing the oral drug dosage forms described herein.

Abstract: In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e. g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e. g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e. g., a drug) or areagent, and/or amount of the compound (e. g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

Abstract: A method of manufacturing a tube is provided. The method includes: selecting a core pipe having a thickness that is initially less than a desired thickness of the tube; and building-up an outer layer over an exterior surface of the core pipe via additive manufacturing so as to increase the thickness of the core pipe such that the thickness of the core pipe is equal to the desired thickness of the tube.

Abstract: Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.